Converge Bio, a Boston- and Tel Aviv-based startup, helps pharmaceutical and biotech companies develop drugs faster with generative AI trained on molecular data, TechCrunch reported in January 2026, when the company raised a $25 million oversubscribed Series A led by Bessemer Venture Partners, with TLV Partners, Saras Capital and Vintage Investment Partners and executives from Meta, OpenAI and Wiz.
The company trains generative models on DNA, RNA and protein sequences and plugs them into customers' drug development workflows, offering ready-to-use systems rather than individual models. It has rolled out three customer-facing systems, for antibody design, protein yield optimisation, and biomarker and target discovery. CEO and co-founder Dov Gertz described the antibody design system as three integrated components: a generative model that creates novel antibodies, predictive models that filter them by molecular properties, and a physics-based docking system that simulates the three-dimensional interaction between antibody and target.
Converge has completed more than 40 programmes with over a dozen pharmaceutical and biotech customers in the U.S., Canada, Europe and Israel and is expanding into Asia. In one published case study it helped a partner boost protein yield by 4 to 4.5 times in a single computational iteration; in another the platform generated antibodies with binding affinity in the single-nanomolar range. The team grew to 34 employees from nine in November 2024, following a $5.5 million seed round in 2024.
Details
- City
- Boston
- Organization
- Converge Bio
- Continent
- North America
- Country
- United States
- Category
- Biotechnology
- Type